Management of patent ductus arteriosus (PDA) remains a challenge for neonatologists in the care of preterm infants. Considering previous findings suggesting that the use of cyclooxygenase inhibitors does not improve long-term prognosis1234) and may cause serious side effects in extremely preterm infants, minimizing their use should be attempted, irrespective of various treatment guidelines recommending prophylactic or symptomatic use.
In recent decades, studies have examined diagnostic methods for PDA and evaluated hemodynamic changes by measuring cardiac biomarkers including B-type natriuretic peptide (BNP) in the neonatal intensive care unit.567) According to a recent meta-analysis, the measurement of BNP has diagnostic value for hemodynamic changes in premature infants with PDA.8)
Jeong et al.9) investigated the usefulness of BNP as a guide for additional ibuprofen dosing in the treatment of PDA in very preterm infants. Additional doses of ibuprofen after the initial dose were withheld if the level of BNP was <600 pg/mL and if the clinical symptoms of PDA improved. The authors avoided unnecessary dosing of ibuprofen without increasing adverse outcomes and showed that the early ductal closure rate on echocardiography was higher in the incomplete dosing group than in the complete dosing group. This report has great significance as it is the first to describe BNP measurement as a guide for individualized treatment of PDA in preterm infants. However, this study did not suggest the absolute level of BNP required to ensure closure of PDA. If data are available or the authors can respond to this issue, they should provide the information for use by other researchers.
Conflicts of interest: No potential conflict of interest relevant to this article was reported.
CookeLSteerPWoodgatePIndomethacin for asymptomatic patent ductus arteriosus in preterm infants20032CD00374512804488FowliePWDavisPGMcGuireWProphylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants20107CD00017420614421OhlssonAWaliaRShahSSIbuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants20152CD00348125692606OhlssonAShahSSIbuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants20117CD00421321735396ChoiBMLeeKHEunBLYooKHHongYSSonCSUtility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants2005115e255e26115687418LeeJHShinJHParkKHRhieYJParkMSChoiBMCan early Btype natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?201310311812223182972CzernikCLemmerJMetzeBKoehnePSMuellerCObladenMB-type natriuretic peptide to predict ductus intervention in infants <28 weeks20086428629018414139KulkarniMGokulakrishnanGPriceJFernandesCJLeeflangMPammiMDiagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review2015135e510e52525601976JeongHAShinJKimELeeEHChoiBMSonCSCorrelation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus20165918318927186229